Epratuzumab
| EAS | Nº pacientes | Respuesta terapéutica n (%) |
Efectos adversos n (%) |
Mortalidad n (%) |
|---|---|---|---|---|
LES |
14 |
14 (100%) |
10 (71%) |
0 (0%) |
| SJOGREN | 16 |
7(44%) |
10(62%) |
0(0%) |
TOTAL |
30 |
14 (100%) |
10 (71%) |
0 (0%) |